ONO Pharmaceutical Co ((OPHLF)) announced an update on their ongoing clinical study.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Study Overview: ONO Pharmaceutical Co. Ltd is conducting a Phase IIa clinical trial titled A Phase IIa, Randomized, Double-blind, Placebo Controlled, Parallel Group, Multi-center Trial to Evaluate the Efficacy and Safety of ONO-1110 in Patients With Major Depressive Disorder. The study aims to assess the efficacy and safety of ONO-1110 in treating Major Depressive Disorder (MDD), a significant mental health condition affecting millions worldwide.
Intervention/Treatment: The trial tests ONO-1110, an experimental drug administered as a tablet once daily, against a placebo. The purpose is to determine ONO-1110’s effectiveness in alleviating symptoms of MDD.
Study Design: This interventional study is randomized and employs a parallel assignment model. It is double-blind, meaning neither participants nor investigators know who receives the drug or placebo, ensuring unbiased results. The primary goal is treatment-focused.
Study Timeline: The study began on January 19, 2025, with primary completion expected soon. The latest update was submitted on June 1, 2025. These dates are crucial for tracking progress and anticipating results.
Market Implications: This update could influence ONO Pharmaceutical’s stock performance positively, as successful results might enhance investor confidence and market position in the competitive pharmaceutical industry. Competitors in the MDD treatment market will be closely monitoring these developments.
Closing Sentence: The study is ongoing, with further details available on the ClinicalTrials portal.